Biotech Stock Crumbles Despite Esperion Nabbing A Key Drug Approval

ALLISON GATLIN
Biotech Stock Crumbles Despite Esperion Nabbing A Key Drug Approval

Shares of Esperion Therapeutics crumbled Friday after the biotech company's cholesterol medicine gained Food and Drug Administration approval. Nexletol aims to lower "bad" LDL cholesterol.